Patents by Inventor Catherine Mary Woods

Catherine Mary Woods has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-alpha2 integrin antibodies and their uses
    Patent number: 8759009
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: June 24, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
  • ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES
    Publication number: 20110135635
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Application
    Filed: August 17, 2010
    Publication date: June 9, 2011
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
  • Anti-?2 integrin antibodies and their uses
    Patent number: 7807794
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: October 5, 2010
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard